Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
38
CGEN Quote, Financials, Valuation and Earnings
Last price:
$1.62
Seasonality move
:
15.89%
Day range:
$1.51 - $1.63
52-week range:
$1.35 - $3.03
Dividend yield:
0%
P/E ratio:
53.33x
P/S ratio:
2.39x
P/B ratio:
2.37x
Volume:
224K
Avg. volume:
451.6K
1-year change:
-4.76%
Market cap:
$143.3M
Revenue:
$33.5M
EPS (TTM):
$0.03
Analysts' Opinion
-
Consensus RatingCompugen has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Compugen has an estimated upside of 150% from its current price of $1.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.60.
Fair Value
-
According to the consensus of 0 analysts, Compugen has 150% upside to fair value with a price target of -- per share.
CGEN vs. S&P 500
-
Over the past 5 trading days, Compugen has underperformed the S&P 500 by -2.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Compugen does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Compugen has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Compugen reported revenues of $17.1M.
Earnings Growth
-
Compugen has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Compugen reported earnings per share of $0.01.
Enterprise value:
30.6M
EV / Invested capital:
0.51x
Price / LTM sales:
2.39x
EV / EBIT:
2.89x
EV / Revenue:
0.51x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.49x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
2.89x
Gross Profit (TTM):
$50.6M
Return On Assets:
1.49%
Net Income Margin (TTM):
2.67%
Return On Equity:
2.69%
Return On Invested Capital:
2.69%
Operating Margin:
26.24%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $59.9M | -- | $17.1M | |
| Gross Profit | -- | -- | $50.6M | -- | $13.5M | |
| Operating Income | -$40.6M | -$34.5M | $10.6M | -$10.6M | $4.5M | |
| EBITDA | -$40.6M | -$34.5M | $10.6M | -$10.6M | $4.5M | |
| Diluted EPS | -$0.46 | -$0.37 | $0.03 | -$0.11 | $0.01 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $134.1M | $112.3M | $91M | $60.3M | $114.8M | |
| Total Assets | $143.4M | $121.3M | $99.4M | $67.6M | $123.5M | |
| Current Liabilities | $7.9M | $15.3M | $14.8M | $10.4M | $27.8M | |
| Total Liabilities | $16.1M | $22.5M | $19.5M | $14.4M | $63M | |
| Total Equity | $127.2M | $98.8M | $79.8M | $53.2M | $60.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2021-06-30 | 2022-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$13.6M | -$20.7M | |
| Cash From Investing | -- | -- | -- | $13.4M | $20.2M | |
| Cash From Financing | -- | -- | -- | $909K | $353K | |
| Free Cash Flow | -$51.4M | -$49.9M | -$62.9M | -$13.8M | -$20.9M | |
CGEN
Sector
Market Cap
$143.3M
$46.1M
Price % of 52-Week High
52.8%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-4.76%
-30.52%
Beta (5-Year)
2.588
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$1.56
200-day SMA
Sell
Level
$1.91
Bollinger Bands (100)
Sell
Level
1.56 - 1.88
Chaikin Money Flow
Sell
Level
-137.3M
20-day SMA
Buy
Level
$1.58
Relative Strength Index (RSI14)
Buy
Level
52.80
ADX Line
Buy
Level
17.16
Williams %R
Neutral
Level
-36
50-day SMA
Sell
Level
$1.60
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
141.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.7787)
Buy
CA Score
(Annual)
Level (-0.1313)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (1.3979)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Stock Forecast FAQ
In the current month, CGEN has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CGEN average analyst price target in the past 3 months is --.
-
Where Will Compugen Stock Be In 1 Year?
According to analysts, the consensus estimate is that Compugen share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Compugen?
Analysts are divided on their view about Compugen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Compugen is a Sell and believe this share price will drop from its current level to --.
-
What Is Compugen's Price Target?
The price target for Compugen over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CGEN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Compugen is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CGEN?
You can purchase shares of Compugen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Compugen shares.
-
What Is The Compugen Share Price Today?
Compugen was last trading at $1.62 per share. This represents the most recent stock quote for Compugen. Yesterday, Compugen closed at $1.60 per share.
-
How To Buy Compugen Stock Online?
In order to purchase Compugen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 2.02% over the past day.
